Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
OpenAI Rejects Apple Trade Secret Theft Claims 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Milei Threatens Falkland Oil Firms With Sanctions 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Add as a preferred source on Google
SEATTLE and SOUTH SAN FRANCISCO, Calif., March 07, 2018 -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report fourth quarter and year end 2017 financial results after the close of U.S. financial markets on Wednesday, March 14, 2018. Immune Design management will host a webcast and conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on March 14, 2018 to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 844-266-9538 for domestic callers and 216-562-0391 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at http://ir.immunedesign.com/events.cfm and will be archived there for 90 days. A telephone replay of the call will be available for five days by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 3777048.
About Immune Design
Immune Design is a late-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic immune cells to fight cancer and other chronic diseases. CMB305 and G100, the leading product candidates with broad potential in oncology, are based on the company’s two technology platforms that are potent stimulators of the immune system: ZVex® and GLAAS®. Both ZVex and GLAAS also have potential applications in infectious disease and allergy indications, which are being developed through ongoing pharmaceutical collaborations. Immune Design has offices in Seattle and South San Francisco. For more information, please visit www.immunedesign.com.
Media Contact
Julie Rathbun
Rathbun Communications
[email protected]
206-769-9219
Investor Contact
Sylvia Wheeler
[email protected]
